DGAP-News

Abivax publishes Universal Registration Document 2021 'Document d'Enregistrement Universel'

DGAP-News: ABIVAX / Key word(s): Miscellaneous Abivax publishes Universal Registration Document 2021 'Document d'Enregistrement Universel' 30.04.2021 / 18:00 The issuer is solely responsible for the content of this announcement. Abivax publishes Universal Registration Document 2021 "Document d'Enregistrement Universel"

PARIS, France, April 30, 2021 - 06:00 p.m. (CEST) - Abivax SA (Euronext Paris: FR0012333284 - ABVX), a clinical-stage biotechnology company developing novel therapies that modulate the immune system to treat chronic inflammatory diseases, viral infections, and cancer, announces today the publication of its 2021 Universal Registration Document (Document d'Enregistrement Universel 2021), filed with the French Financial Market Authorities, Autorité des Marchés Financiers (AMF), on April 30, 2021.

The Registration Document includes the 2020 Annual Report and the corporate governance report, prepared by the Board of Directors, as well as the conclusions of the statutory auditors.

Copies of the document are available free of charge at the Abivax headquarters on 5, rue de la Baume, 75008 Paris as well as in electronic form via the website of both Abivax (www.abivax.com) and the French Financial Market Authorities (www.amf-france.org). An English translation of the Universal Registration Document will be available on May 7, 2021 at the latest.

*****

About Abivax (www.abivax.com)

Abivax, a clinical stage biotechnology company, is developing novel therapies that modulate the body's natural immune machinery to treat patients with chronic inflammatory diseases, viral infections, and cancer. Abivax is listed on Euronext compartment B (ISIN: FR0012333284 - Mnémo: ABVX). Based in Paris and Montpellier, Abivax has two drug candidates in clinical development, ABX464 to treat severe inflammatory diseases, and ABX196 to treat hepatocellular carcinoma. More information on the company is available at www.abivax.com. Follow us on Twitter @ABIVAX_.